{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:04:33Z","timestamp":1792735473219,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.amjmed.2022.01.006","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T06:20:25Z","timestamp":1643610025000},"page":"S13-S19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"S1","title":["Neuromuscular Complications of Systemic Amyloidosis"],"prefix":"10.1016","volume":"135","author":[{"given":"Dina","family":"Namiranian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Geisler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.amjmed.2022.01.006_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/asheducation-2017.1.1","article-title":"AL amyloidosis: from molecular mechanisms to targeted therapies","volume":"2017","author":"Merlini","year":"2017","journal-title":"Hematology"},{"issue":"7","key":"10.1016\/j.amjmed.2022.01.006_bib0002","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","article-title":"Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease","volume":"15","author":"Adams","year":"2019","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"10.1016\/j.amjmed.2022.01.006_bib0003","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jama.2020.5493","article-title":"Systemic amyloidosis recognition, prognosis, and therapy: a systematic review","volume":"324","author":"Gertz","year":"2020","journal-title":"JAMA"},{"issue":"17","key":"10.1016\/j.amjmed.2022.01.006_bib0004","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.jacc.2018.07.092","article-title":"Tenosynovial and Cardiac Amyloidosis in Patients Undergoing Carpal Tunnel Release","volume":"72","author":"Sperry","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.amjmed.2022.01.006_bib0005","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0002-9343(98)00037-0","article-title":"Prognosis of patients with primary systemic amyloidosis who present with dominant neuropathy","volume":"104","author":"Rajkumar","year":"1998","journal-title":"Am J Med"},{"issue":"10","key":"10.1016\/j.amjmed.2022.01.006_bib0006","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.mayocp.2016.06.027","article-title":"Systemic immunoglobulin light chain amyloidosis-associated myopathy: presentation, diagnostic pitfalls, and outcome","volume":"91","author":"Muchtar","year":"2016","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"10.1016\/j.amjmed.2022.01.006_bib0007","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1017\/cjn.2020.271","article-title":"Utility of neuropathy screening for wild-type transthyretin amyloidosis patients","volume":"48","author":"Russell","year":"2021","journal-title":"Can J Neurol Sci"},{"issue":"1","key":"10.1016\/j.amjmed.2022.01.006_bib0008","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/mus.26723","article-title":"Transthyretin amyloidosis: putting myopathy on the map","volume":"61","author":"Pinto","year":"2020","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.amjmed.2022.01.006_bib0009","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ajmg.1320600606","article-title":"Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)-type I in P\u00f3voa do Varzim and Vila do Conde (north of Portugal)","volume":"60","author":"Sousa","year":"1995","journal-title":"Am J Med Genet"},{"issue":"5","key":"10.1016\/j.amjmed.2022.01.006_bib0010","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/mus.26034","article-title":"Estimating the global prevalence of transthyretin familial amyloid polyneuropathy","volume":"57","author":"Schmidt","year":"2018","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.amjmed.2022.01.006_bib0011","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1007\/s00415-019-09688-0","article-title":"Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy","volume":"268","author":"Adams","year":"2021","journal-title":"J Neurol"},{"issue":"3","key":"10.1016\/j.amjmed.2022.01.006_bib0012","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1136\/practneurol-2018-002098","article-title":"Diagnosis of amyloid neuropathy","volume":"19","author":"Kapoor","year":"2019","journal-title":"Pract Neurol"},{"issue":"7","key":"10.1016\/j.amjmed.2022.01.006_bib0013","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1212\/01.wnl.0000267338.45673.f4","article-title":"Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP)","volume":"69","author":"Plant\u00e9-Bordeneuve","year":"2007","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.amjmed.2022.01.006_bib0014","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/gim.2016.200","article-title":"Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans","volume":"19","author":"Buxbaum","year":"2017","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.amjmed.2022.01.006_bib0015","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jacc.2021.04.042","article-title":"Atrial fibrillation and ischemic stroke with the amyloidogenic V122I transthyretin variant among black Americans","volume":"78","author":"Selvaraj","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.amjmed.2022.01.006_bib0016","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1212\/WNL.0000000000005777","article-title":"Transthyretin amyloid polyneuropathies mimicking a demyelinating polyneuropathy","volume":"91","author":"Lozeron","year":"2018","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.amjmed.2022.01.006_bib0017","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/13506129.2018.1436048","article-title":"Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR)","volume":"25","author":"Phull","year":"2018","journal-title":"Amyloid"},{"issue":"1","key":"10.1016\/j.amjmed.2022.01.006_bib0018","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/ana.24972","article-title":"Cutaneous nerve biomarkers in transthyretin familial amyloid polyneuropathy","volume":"82","author":"Ebenezer","year":"2017","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.amjmed.2022.01.006_bib0019","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/jns.12350","article-title":"Plasma neurofilament light chain concentration is increased and correlates with the severity of neuropathy in hereditary transthyretin amyloidosis","volume":"24","author":"Kapoor","year":"2019","journal-title":"J Peripher Nerv Syst"},{"issue":"1","key":"10.1016\/j.amjmed.2022.01.006_bib0020","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.amjmed.2022.01.006_bib0021","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934322000262?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934322000262?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:25:25Z","timestamp":1757582725000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934322000262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":21,"alternative-id":["S0002934322000262"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2022.01.006","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuromuscular Complications of Systemic Amyloidosis","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2022.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}